Invesco Biotechnology & Genome ETF
PBE
88 hedge funds and large institutions have $64.3M invested in Invesco Biotechnology & Genome ETF in 2021 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 19 increasing their positions, 23 reducing their positions, and 3 closing their positions.
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
9% more funds holding
Funds holding: 81 → 88 (+7)
8% more capital invested
Capital invested by funds: $59.7M → $64.3M (+$4.59M)
0.5% more ownership
Funds ownership: 23.04% → 23.54% (+0.5%)
17% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FP
Financial Perspectives
Minneapolis,
Minnesota
|
+$1.93M |
| 2 |
Morgan Stanley
New York
|
+$608K |
| 3 |
PFO
Pathstone Family Office
Englewood,
New Jersey
|
+$416K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$246K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$239K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$746K |
| 2 |
KAS
Kestra Advisory Services
Austin,
Texas
|
-$206K |
| 3 |
ACM
Anfield Capital Management
Irvine,
California
|
-$160K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$132K |
| 5 |
COF
Capital One Financial
Mclean,
Virginia
|
-$113K |
PBE Hedge Fund Activity: Q1 2021 in Review
88 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q1 2021, worth a combined $64.3M — up 7.7% from $59.7M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new PBE positions and 3 closed out — a net gain of 7 holders — while 19 added to existing stakes and 23 trimmed.
The largest buyer was Financial Perspectives, adding an estimated $1.93M. The largest seller was Bank of America, cutting an estimated $746K.
- 88 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q1 2021, up from 81 in Q4 2020.
- Funds reported $64.3M of Invesco Biotechnology & Genome ETF stock for Q1 2021, up 7.7% quarter-over-quarter.
- 10 funds opened new Invesco Biotechnology & Genome ETF positions in Q1 2021 and 3 closed out, a net change of +7 holders.
- The largest Invesco Biotechnology & Genome ETF buyer in Q1 2021 was Financial Perspectives, an estimated $1.93M added.
- The largest Invesco Biotechnology & Genome ETF seller in Q1 2021 was Bank of America, an estimated $746K sold.
Based on aggregated 13F filings for Q1 2021.